Phase I/II CANON study: oncolytic immunotherapy for the treatment of non-muscle invasive bladder (NMIBC) cancer using intravesical coxsackievirus A21

被引：2
|
作者：
Pandha, H. S. [1 ]
Annels, N. [1 ]
Arif, M. [1 ]
Mostafid, H. [1 ]
Sandhu, S. [2 ]
Harrington, K. [3 ]
Melcher, A. [4 ]
Mansfield, D. [3 ]
Au, G. [5 ]
Grose, M. [5 ]
Karpathy, R. [5 ]
Shafren, D. [5 ]
机构：
[1] Univ Surrey, Clin & Expt Med, Guildford, Surrey, England
[2] Kingston Hosp, Urol, Kingston, England
[3] ICR, Targeted Therapy, London, England
[4] Leeds Inst Canc & Pathol, Oncol & Clin Res, Leeds, W Yorkshire, England
[5] Viralytics Ltd, Viralyt, Sydney, NSW, Australia
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw378.9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1054PD
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase I/II canon study: Oncolytic immunotherapy for the treatment of non-muscle invasive bladder (NMIBC) cancer using intravesical coxsackievirus A21.
    Pandha, Hardev S.
    Annels, Nicola E.
    Simpson, Guy
    Mostafid, Hugh
    Harrington, Kevin J.
    Melcher, Alan
    Grose, Mark
    Davies, Bronwyn
    Au, Gough Geoffrey
    Karpathy, Roberta
    Shafren, Darren
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [2] Intravesical Coxsackievirus A21 Therapy for Non-Muscle Invasive Bladder Cancer
    Messing, Edward
    BLADDER CANCER, 2020, 6 (01) : 97 - 98
  • [3] A phase I study of intravesical camrelizumab for BCG failure Non-Muscle Invasive Bladder Cancer (NMIBC)
    Wang, Y.
    Xu, P. H.
    Bian, X. J.
    Lu, X. L.
    Wang, Z.
    Wang, X.
    Yao, X. D.
    Shen, Y. J.
    Ye, D. Y.
    EUROPEAN UROLOGY, 2022, 81 : S251 - S251
  • [4] A phase I study to assess the safety and tolerability of intravesical pembrolizumab in recurrent non-muscle invasive bladder cancer (NMIBC).
    Woodcock, Victoria K.
    Purshouse, Karin
    Butcher, Chrissie
    Haddon, Caroline
    Verrall, Gillian
    Elhussein, Leena
    Salio, Mariolina
    Middleton, Mark R.
    Cerundolo, Vincenzo
    Crew, Jeremy
    Protheroe, Andrew
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [5] Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review
    Shelley, Mike D.
    Jones, Gabriel
    Cleves, Anne
    Wilt, Timothy J.
    Mason, Malcolm D.
    Kynaston, Howard G.
    BJU INTERNATIONAL, 2012, 109 (04) : 496 - 505
  • [6] EXPLORING A NOVEL SYNERGISTIC INTRAVESICAL ONCOLYTIC VIROTHERAPY FOR TREATMENT OF NON-MUSCLE INVASIVE BLADDER CANCER
    Smelser, Woodson
    Wang, Jian
    Chang, Sam
    Kirschner, Austin
    JOURNAL OF UROLOGY, 2022, 207 (05): : E78 - E78
  • [7] Study protocol of a phase II clinical trial of oral metformin for the intravesical treatment of non-muscle invasive bladder cancer
    Remco J. Molenaar
    Jons W. van Hattum
    Iris S. Brummelhuis
    Jorg R. Oddens
    C. Dilara Savci-Heijink
    Egbert R. Boevé
    Saskia A. van der Meer
    J. Fred Witjes
    Michael N. Pollak
    Theo M. de Reijke
    Johanna W. Wilmink
    BMC Cancer, 19
  • [8] Study protocol of a phase II clinical trial of oral metformin for the intravesical treatment of non-muscle invasive bladder cancer
    Molenaar, Remco J.
    van Hattum, Jons W.
    Brummelhuis, Iris S.
    Oddens, Jorg R.
    Savci-Heijink, C. Dilara
    Boeve, Egbert R.
    van der Meer, Saskia A.
    Witjes, J. Fred
    Pollak, Michael N.
    de Reijke, Theo M.
    Wilmink, Johanna W.
    BMC CANCER, 2019, 19 (01)
  • [9] Efficacy of combined intravesical immunotherapy and chemotherapy for non-muscle invasive bladder cancer
    Hilton, William M.
    Ercole, Barbara
    Parekh, Dipen J.
    Sonpavde, Guru
    Ghosh, Rita
    Svatek, Robert S.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2011, 11 (06) : 949 - 957
  • [10] INTRAVESICAL THERAPY FOLLOWING TREATMENT OF NON-MUSCLE INVASIVE BLADDER CANCER
    Wang, Wei
    INTERNATIONAL JOURNAL OF UROLOGY, 2012, 19 : 36 - 36
12345